Stoke Therapeutics, Inc.
STOK · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $11 | $14 | $159 | $23 |
| % Growth | -23.1% | -91.3% | 601.2% | – |
| Cost of Goods Sold | $1 | $0 | $0 | $0 |
| Gross Profit | $10 | $14 | $159 | $23 |
| % Margin | 90.7% | 100% | 100% | 100% |
| R&D Expenses | $37 | $26 | $33 | $23 |
| G&A Expenses | $0 | $15 | $15 | $13 |
| SG&A Expenses | $15 | $15 | $15 | $13 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $53 | $41 | $47 | $36 |
| Operating Income | -$43 | -$27 | $111 | -$14 |
| % Margin | -405.3% | -197.6% | 70.2% | -60.4% |
| Other Income/Exp. Net | $3 | $4 | $3 | $3 |
| Pre-Tax Income | -$40 | -$23 | $114 | -$10 |
| Tax Expense | -$1 | $0 | $1 | $0 |
| Net Income | -$38 | -$23 | $113 | -$10 |
| % Margin | -360.7% | -170% | 71.2% | -46.4% |
| EPS | -0.65 | -0.4 | 1.95 | -0.18 |
| % Growth | -62.5% | -120.5% | 1,183.3% | – |
| EPS Diluted | -0.65 | -0.4 | 1.9 | -0.18 |
| Weighted Avg Shares Out | 59 | 58 | 58 | 57 |
| Weighted Avg Shares Out Dil | 59 | 58 | 59 | 57 |
| Supplemental Information | – | – | – | – |
| Interest Income | $3 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $1 | $0 | $0 | $1 |
| EBITDA | -$39 | -$27 | $112 | -$13 |
| % Margin | -363.4% | -194.4% | 70.5% | -58% |